Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
Target-specific de novo design of drug candidate molecules with graph-transformer-based generative adversarial networks
Date
2025-01-01
Author
Ünlü, Atabey
Çevrim, Elif
Yiğit, Melih Gökay
Sarıgün, Ahmet
Çelikbilek, Hayriye
Bayram, Osman
Kahraman, Deniz Cansen
OLĞAÇ, ABDURRAHMAN
Rifaioglu, Ahmet Sureyya
BANOĞLU, ERDEN
Doğan, Tunca
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
194
views
0
downloads
Cite This
Discovering novel drug candidate molecules is a fundamental step in drug development. Generative deep learning models can sample new molecular structures from learned probability distributions; however, their practical use in drug discovery hinges on generating compounds tailored to a specific target molecule. Here we introduce DrugGEN, an end-to-end generative system for the de novo design of drug candidate molecules that interact with a selected protein. The proposed method represents molecules as graphs and processes them using a generative adversarial network that comprises graph transformer layers. Trained on large datasets of drug-like compounds and target-specific bioactive molecules, DrugGEN designed candidate inhibitors for AKT1, a kinase crucial in many cancers. Docking and molecular dynamics simulations suggest that the generated compounds effectively bind to AKT1, and attention maps provide insights into the model’s reasoning. Furthermore, selected de novo molecules were synthesized and shown to inhibit AKT1 at low micromolar concentrations in the context of in vitro enzymatic assays. These results demonstrate the potential of DrugGEN for designing target-specific molecules. Using the open-access DrugGEN codebase, researchers can retrain the model for other druggable proteins, provided a dataset of known bioactive molecules is available.
URI
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105016145677&origin=inward
https://hdl.handle.net/11511/115743
Journal
Nature Machine Intelligence
DOI
https://doi.org/10.1038/s42256-025-01082-y
Collections
Graduate School of Informatics, Article
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
A. Ünlü et al., “Target-specific de novo design of drug candidate molecules with graph-transformer-based generative adversarial networks,”
Nature Machine Intelligence
, pp. 0–0, 2025, Accessed: 00, 2025. [Online]. Available: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105016145677&origin=inward.